96 related articles for article (PubMed ID: 31747239)
1. Prescribing trend of pioglitazone after safety warning release in Korea.
Jeong HE; Cho SI; Oh IS; Baek YH; Shin JY
Am J Manag Care; 2019 Nov; 25(11):e342-e348. PubMed ID: 31747239
[TBL] [Abstract][Full Text] [Related]
2. Do cost containment policies save money and influence physicians' prescribing behavior? Lessons from South Korea's drug policy for diabetes medication.
Kang SO; Kim SJ; Park S; Jang SI; Park EC
Int J Qual Health Care; 2019 Mar; 31(2):96-102. PubMed ID: 29788203
[TBL] [Abstract][Full Text] [Related]
3. Study design choices for evaluating the comparative safety of diabetes medications: An evaluation of pioglitazone use and risk of bladder cancer in older US adults with type-2 diabetes.
Garry EM; Buse JB; Gokhale M; Lund JL; Nielsen ME; Pate V; Stürmer T
Diabetes Obes Metab; 2019 Sep; 21(9):2096-2106. PubMed ID: 31087620
[TBL] [Abstract][Full Text] [Related]
4. A word of caution regarding pioglitazone.
Usman MS; Rizwan T; Ahmed F
J Pak Med Assoc; 2017 Jan; 67(1):153. PubMed ID: 28065979
[No Abstract] [Full Text] [Related]
5. Effect of pioglitazone in acute ischemic stroke patients with diabetes mellitus: a nested case-control study.
Woo MH; Lee HS; Kim J
Cardiovasc Diabetol; 2019 May; 18(1):67. PubMed ID: 31151454
[TBL] [Abstract][Full Text] [Related]
6. Changes and predictors for change to thiazolidinedione prescribing in UK primary care following the rosiglitazone safety warning.
Hall GC; Smith HT; Curtis B; McMahon AD
Int J Clin Pract; 2011 May; 65(5):586-91. PubMed ID: 21489082
[TBL] [Abstract][Full Text] [Related]
7. Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes.
Lewis JD; Habel LA; Quesenberry CP; Strom BL; Peng T; Hedderson MM; Ehrlich SF; Mamtani R; Bilker W; Vaughn DJ; Nessel L; Van Den Eeden SK; Ferrara A
JAMA; 2015 Jul; 314(3):265-77. PubMed ID: 26197187
[TBL] [Abstract][Full Text] [Related]
8. Pioglitazone and bladder cancer risk: a systematic review and meta-analysis.
Tang H; Shi W; Fu S; Wang T; Zhai S; Song Y; Han J
Cancer Med; 2018 Apr; 7(4):1070-1080. PubMed ID: 29476615
[TBL] [Abstract][Full Text] [Related]
9. Impact of clinical evidence communications and drug regulation changes concerning rosiglitazone on prescribing patterns of antidiabetic therapies.
Noh Y; Kang DR; Kim DJ; Lee KJ; Lee S; Shin S
Pharmacoepidemiol Drug Saf; 2017 Nov; 26(11):1338-1346. PubMed ID: 28771933
[TBL] [Abstract][Full Text] [Related]
10. Impact of regulatory spin of pioglitazone on prescription of antidiabetic drugs among physicians in India: A multicentre questionnaire-based observational study.
Goyal A; Singh H; Sehgal VK; Jayanthi CR; Munshi R; Bairy KL; Kumar R; Kaushal S; Kakkar AK; Ambwani S; Goyal C; Mazumdar G; Adhikari A; Das N; Stephy DJ; Thangaraju P; Dhasmana DC; Rehman SU; Chakrabarti A; Bhandare B; Badyal DK; Kaur I; Chandrashekar K; Singh J; Dhamija P; Sarangi SC; Gupta YK
Indian J Med Res; 2017 Oct; 146(4):468-475. PubMed ID: 29434060
[TBL] [Abstract][Full Text] [Related]
11. Pioglitazone and PPAR-γ modulating treatment in hypertensive and type 2 diabetic patients after ischemic stroke: a national cohort study.
Liu CH; Lee TH; Lin YS; Sung PS; Wei YC; Li YR
Cardiovasc Diabetol; 2020 Jan; 19(1):2. PubMed ID: 31910836
[TBL] [Abstract][Full Text] [Related]
12. Changes in glitazone use among office-based physicians in the U.S., 2003-2009.
Cohen A; Rabbani A; Shah N; Alexander GC
Diabetes Care; 2010 Apr; 33(4):823-5. PubMed ID: 20103549
[TBL] [Abstract][Full Text] [Related]
13. Pioglitazone use associated with reduced risk of the first attack of ischemic stroke in patients with newly onset type 2 diabetes: a nationwide nested case-control study.
Ha J; Choi DW; Kim KY; Nam CM; Kim E
Cardiovasc Diabetol; 2021 Jul; 20(1):152. PubMed ID: 34315501
[TBL] [Abstract][Full Text] [Related]
14. Comparative safety of pioglitazone versus clinically meaningful treatment alternatives concerning the risk of bladder cancer in older US adults with type 2 diabetes.
Garry EM; Buse JB; Lund JL; Pate V; Stürmer T
Diabetes Obes Metab; 2018 Jan; 20(1):129-140. PubMed ID: 28661561
[TBL] [Abstract][Full Text] [Related]
15. Global and Regional Effects of Bladder Cancer Risk Associated with Pioglitazone Therapy in Patients with Diabetes.
Qu H; Zheng Y; Wang Y; Zhang R; Ruan X; Yang G; Liu Z; Zheng H
Sci Rep; 2017 Nov; 7(1):15804. PubMed ID: 29150684
[TBL] [Abstract][Full Text] [Related]
16. Trends in the prescription of antidiabetic medications in France: evidence from primary care physicians.
Boyc KS; Yurgin N; Lage MJ
Adv Ther; 2007; 24(4):803-13. PubMed ID: 17901029
[TBL] [Abstract][Full Text] [Related]
17. Risk of bladder cancer among patients with diabetes treated with a 15 mg pioglitazone dose in Korea: a multi-center retrospective cohort study.
Jin SM; Song SO; Jung CH; Chang JS; Suh S; Kang SM; Jung I; Park CY; Kim JH; Cho JH; Lee BW
J Korean Med Sci; 2014 Feb; 29(2):238-42. PubMed ID: 24550651
[TBL] [Abstract][Full Text] [Related]
18. Effects of safety warnings and risk management plan for Thiazolidinediones in Taiwan.
Hsu JC; Cheng CL; Ross-Degnan D; Wagner AK; Zhang F; Kao Yang YH; Liu LL; Tai HY; Chen KH; Yang PW; Lu CY
Pharmacoepidemiol Drug Saf; 2015 Oct; 24(10):1026-35. PubMed ID: 26251229
[TBL] [Abstract][Full Text] [Related]
19. Pioglitazone use in Australia and the United Kingdom following drug safety advisories on bladder cancer risk: An interrupted time series study.
Kemp-Casey A; Mintzes B; Morrow RL; Dormuth CR; Souverein PC; Roughead EE
Pharmacoepidemiol Drug Saf; 2022 Oct; 31(10):1039-1045. PubMed ID: 35790047
[TBL] [Abstract][Full Text] [Related]
20. Impact of pioglitazone regulatory withdrawal on antidiabetic drug use and health in diabetic patients.
Pariente A; Mansiaux Y; Jarné A; Salvo F; Pageot C; Bezin J; Smith A; Bégaud B
Eur J Clin Pharmacol; 2017 Dec; 73(12):1655-1663. PubMed ID: 28866826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
